Authors: Savarese, DM Halabi, S Hars, V Akerley, WL Taplin, ME Godley, PA Hussain, A Small, EJ Vogelzang, NJ

Citation: Dm. Savarese et al., Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780, J CL ONCOL, 19(9), 2001, pp. 2509-2516

Authors: Taplin, ME Bubley, GJ Rajeshkumar, B Shuster, T Ko, YJ Morganstern, DE

Citation: Me. Taplin et al., Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer, SEMIN ONCOL, 28(4), 2001, pp. 32-39

Authors: Taplin, ME Ho, SM

Citation: Me. Taplin et Sm. Ho, The endocrinology of prostate cancer, J CLIN END, 86(8), 2001, pp. 3467-3477

Authors: Leav, I Lau, KM Adams, JY McNeal, JE Taplin, ME Wang, JF Singh, H Ho, SM

Citation: I. Leav et al., Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary andmetastatic carcinoma, AM J PATH, 159(1), 2001, pp. 79-92

Authors: Savarese, D Taplin, ME Halabi, S Hars, V Kreis, W Vogelzang, N

Citation: D. Savarese et al., A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of cancer and leukemia group B trial 9780, SEMIN ONCOL, 26(5), 1999, pp. 39-44

Authors: Taplin, ME Bubley, GJ Ko, YJ Small, EJ Upton, M Rajeshkumar, B Balk, SP

Citation: Me. Taplin et al., Selection for androgen receptor mutations in prostate cancers treated withandrogen antagonist, CANCER RES, 59(11), 1999, pp. 2511-2515